The drug fluorouracil (5-FU) is a widely used antimetabolite chemotherapy in the treatment of colorectal cancer. The gene uridine monophosphate synthetase (UMPS) is thought to be primarily responsible for conversion of 5-FU to active anticancer metabolites in tumor cells. Mutation or aberrant expression of UMPS may contribute to 5-FU resistance during treatment. We undertook a characterization of UMPS mRNA isoform expression and sequence variation in 5-FU-resistant cell lines and drug-naive or -exposed primary and metastatic tumors. We observed reciprocal differential expression of two UMPS isoforms in a colorectal cancer cell line with acquired 5-FU resistance relative to the 5-FU-sensitive cell line from which it was derived. A novel isoform arising as a consequence of exon skipping was increased in abundance in resistant cells. The underlying mechanism responsible for this shift in isoform expression was determined to be a heterozygous splice site mutation acquired in the resistant cell line. We developed sequencing and expression assays to specifically detect alternative UMPS isoforms and used these to determine that UMPS was recurrently disrupted by mutations and aberrant splicing in additional 5-FU-resistant colorectal cancer cell lines and colorectal tumors. The observed mutations, aberrant splicing and downregulation of UMPS represent novel mechanisms for acquired 5-FU resistance in colorectal cancer.
The drug fluorouracil (5-FU) is an antimetabolite chemotherapy commonly used in the treatment of several cancer types including head and neck, pancreatic, breast, stomach and colorectal. 1, 2 Intrinsic or acquired resistance to 5-FU is a major limiting factor in the treatment of colorectal and other cancers. Response rates for 5-FU vary from 6 to 53% depending on dose, schedule, combination with modifiers and disease characteristics. 3 Because of the high usage and lowto-moderate response rates for 5-FU, the clinical relevance of 5-FU resistance is considerable. Resistance to 5-FU is hypothesized to arise by a number of mechanisms, and previous studies have primarily focused on 5-FU metabolism genes. The uridine monophosphate synthetase (UMPS) expression level has been described as potentially critical to the response of a tumor to 5-FU and is cited as the primary means of activating the prodrug 5-FU to active antitumor metabolites. 4, 5 A number of previous studies have reported attempts to use UMPS expression as a predictor of drug response with varying degrees of success. Some of these studies suggested that measuring UMPS expression is useful in predicting 5-FU response, [6] [7] [8] whereas others claimed that UMPS expression was not correlated with 5-FU response. [9] [10] [11] [12] Many of these studies employed a strategy that involved measuring the expression of UMPS by use of probes targeting the 3 0 end of the canonical UMPS transcript without regard to potential alternative isoforms (Supplementary Table 1 ). Other studies employed biochemical assays of enzymatic activity that do not rely on inference, but are difficult to apply in clinical settings and require large amounts of fresh tumor tissue. Developing methods to predict and ultimately overcome this resistance remains an active area of research.
The use of genomic methods to identify the molecular causes of disease phenotypes is expanding. 13 We recently developed two novel genome-wide approaches to profile alternatively processed transcripts. The first method uses splicing microarrays for 'alternative expression analysis' (ALEXA) 14 and the second uses an Illumina DNA sequencer for alternative expression analysis by RNA sequencing (ALEXA-seq). 15 Using these approaches, we observed differential expression of UMPS isoforms in a colorectal cancer cell line with acquired 5-FU resistance relative to the sensitive cell line from which it was derived. In this study, we used reverse transcriptase-PCR (RT-PCR) and quantitative real-time RT-PCR to validate these differential expression observations and surveyed the expression of the two most abundant isoforms in additional sensitive/resistant cell lines and a panel of 26 colorectal cancer tumor/normal pairs. We cataloged the diversity of UMPS transcript variation in these cell lines by cloning, sequencing and analysis of 293 UMPS complementary DNAs (cDNAs). We then performed genomic DNA sequencing of the UMPS locus in 6 cell lines and 91 pre-and post-treatment colorectal cancer patient samples to identify mutations that might account for differential expression of isoforms or affect UMPS function. We identified protein coding and splice site mutations affecting the UMPS OPRTase domain (the catalytic domain responsible for 5-FU activation 16 ) in three 5-FU-resistant cell lines and additional protein coding and splice site mutations in patient tumors. To our knowledge, no previous study examining UMPS mRNA expression has considered the presence of alternatively spliced or mutated variant isoforms or has performed transcript resequencing to characterize their diversity.
Materials and methods

Cell lines
The 5-FU-sensitive cell lines MIP101, 17 HCT116 and RKO and their respective 5-FU-resistant cell lines MIP/5FU, 18 RKO/5FU and HCT/5FU were maintained in Dulbecco's modified Eagle's medium or RPMI media supplemented with 1% penicillin-streptomycin, 1% kanamycin and 10% newborn calf serum or fetal bovine serum at 37 1C and 5% CO 2 . 18 For previously described resistant cell lines, 18 media were also supplemented as follows: MIP/5FU 500 mM 5-FU; RKO/5FU 25 mM 5-FU; and HCT/5FU 10 mM 5-FU. 
Clinical samples
Nucleic acid isolation
Total RNA was isolated from cells using TRIzol (Invitrogen, ON, Canada) and/or the RNeasy Mini Kit (Qiagen, ON, Canada). RNA was treated using an RNase-free DNase I kit (Invitrogen). In some cases, polyA þ RNA was purified from total RNA using an OligoTex kit (Qiagen). Genomic DNA was isolated through homogenization of tissues (B20 mg of frozen tissue or two 10 mM scrolls of formalin-fixed, paraffinembedded) or cell lines (B75% confluent) followed by extraction with the Gentra Puregene kit (Qiagen). A reference genomic DNA sample was obtained from Clontech (Mountain View, CA, USA, Cat. no. 636401).
Splicing microarray analysis
Creation of custom 'ALEXA' splicing microarray designs, sample preparation, microarray hybridization and analysis of microarray data were performed as previously described.
14 Additional details are provided online at www.AlexaPlatform.org.
Whole transcriptome shotgun sequencing and analysis Library construction, Illumina (San Diego, CA) sequencing, read mapping and analysis were as previously described. 15 Quantitative real time RT-PCR Single-stranded cDNA was generated from total RNA according to the manufacturer's recommendations using SuperScript III Reverse Transcriptase (Invitrogen). Up to 1 mg no. SM0671). Specificity of the UMPS antibody was determined by small interfering RNA (siRNA) knockdown of UMPS using three siRNAs (Ambion, Grand Island, NY; siRNAs, ID:s14672, ID:s14674, and ID:s110645) and two scramble siRNAs (Ambion siRNAs: cat. no. 4390843 and AM4613; see Supplementary Methods and Materials).
PCR and sequencing the UMPS locus
The UMPS locus was sequenced by generating 44 amplicons covering all 6 exons and at least 50 bp of flanking intron sequence. These PCR amplicons were generated using genomic DNA from 6 cell lines and 118 patient samples. Each primer contained either an M13F or M13R linker that was used for direct sequencing (see Supplementary Table 2 for primer sequences). PCR was performed with Platinum Taq High Fidelity enzyme (Invitrogen). Amplicons were purified using Agencourt Ampure Beads (Agencourt Biosciences, Beverly, MA, USA) and Sanger sequenced using M13F and M13R primers and previously published reaction chemistries. 19 The success rate for PCRs (defined as a single visible band observed by gel electrophoresis) was 86 to 100% for the 44 amplicons (mean ¼ 95%). The mean number of sequence bases with a Phred quality 20, 21 of X20 ranged from 55 to 89% across the 44 amplicons (mean ¼ 79%). Mutation Surveyor (SoftGenetics, State College, PA) was used to identify mutations.
Determining the half-maximal growth inhibition constant (GI 50 ) using the alamarBlue assay Cells were counted and diluted in media (RPMI supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 1% kanamycin) to a concentration of 40 000 cells per ml for MIP101 and 60 000 cells per ml for MIP/5FU. Cells were plated in seven rows of a 96-well plate. One row of the plate contained media only. The next day, cells were treated with 12 concentrations of 5-FU, including 0 mM (7 replicates for each drug concentration). After 48 h of incubation with the drug, each well was incubated for 2 h with alamarBlue dye (Invitrogen). Fluorescent readings were assessed using the Tecan Safire2 microplate reader (Invitrogen).
Additional Methods and Materials are available as Supplementary Materials.
Results
Novel UMPS mRNA isoforms identified in 5-FU-resistant lines
We previously applied custom-designed alternative expression analysis (ALEXA) microarrays to profile polyA þ RNA from MIP101 (5-FU sensitive) and MIP/5FU (5-FU resistant) colorectal cancer cell lines. 14 The data revealed differential expression of two UMPS isoforms (A and B). Isoform A matches the reference sequence (NM_000373) in that it has six exons, whereas isoform B does not have exon 2 ( Figure 1 ). The same differential expression of isoforms was supported by ALEXA-seq analysis of RNA-Seq data. 15 Specifically, in the MIP101 RNA-Seq library, 98% of mapped reads corresponded to the canonical UMPS isoform A (A/B ¼ 51.4). In contrast, in the MIP/5FU RNA-Seq library, an approximately equal ratio of reads supporting the exonexon junctions of UMPS isoforms A and B was observed (A/B ¼ 0.8). Both isoforms could be detected in all six cell lines ( Table 1, Supplementary Figure 1 and Supplementary  Tables 3 and 4) . Isoform A was 4-to 5-fold less abundant in MIP/5FU cells relative to MIP101 (Supplementary Table 3b ). Isoform B was ninefold more abundant in MIP/5FU and fivefold more abundant in HCT/5FU cells relative to MIP101 and HCT116, respectively (Tables 1 and 2 and Supplementary Table 3 ). The difference in abundance of each isoform between RKO and RKO/5FU was small (Tables 1 and 2 and  Supplementary Table 3) . 0.05±0.01, P ¼ 0.32, n ¼ 3; MIP/5FU treated 0.59±0.27 vs untreated 0.59±0.14, P ¼ 0.96, n ¼ 3). There was also no significant change at this time point and the respective drug concentrations by immunoblot in the levels of UMPS protein (MIP101 treated/untreated ¼ 1.37-fold, P ¼ 0.41, n ¼ 3; MIP/5FU treated/untreated ¼ 0.94, P ¼ 0.77, n ¼ 3; see Supplementary Results and Figures 2-4) .
We further characterized the structural diversity of UMPS mRNA isoforms by generating and sequencing clones representing a total of 10 alternative isoforms (Supplementary Results, Supplementary Figures 1 and 5 and Supplementary Tables 4-7) . The majority of these appear to maintain the reading frame of UMPS but result in some removal of protein coding sequence. In addition, we surveyed UMPS isoform expression patterns in treatmentnaive colorectal tumor samples (Supplementary Results and Supplementary Figures 6 and 7) . Isoform B appears to be widely expressed but generally at lower levels than isoform A.
UMPS knockdown and 5-FU resistance in MIP101 cell lines
Compared with the parent MIP101-sensitive cell line, the derivative MIP/5FU-resistant cell line had different levels of UMPS isoform A (Po0.0001) and B (P ¼ 0.03) mRNA, lower levels of UMPS protein (P ¼ 0.01) and a higher GI 50 (MIP101 GI 50 (95% confidence interval (CI)) ¼ 2.9 mM (1.6-5.2) versus negative control GI 50 (95% CI) ¼ 633 mM (379-1058), Po0.0001; Figure 2 ). To assess if the lower UMPS in MIP/5FU contributes to their greater 5-FU resistance, UMPS was knocked down using siRNA in the sensitive MIP101 cell line. Both UMPS isoform A and isoform B decreased by B70% (Po0.0001 and 0.001, respectively), UMPS protein decreased by 39% (P ¼ 0.003) and the GI 50 was threefold increased (UMPS knockdown GI 50 (95% CI (Figure 3 and Supplementary Figure 4) .
Sequencing of UMPS in 5-FU-sensitive and -resistant cell lines
We hypothesized that mutations acquired at the UMPS locus during the selection of 5-FU resistance might be responsible for the altered splicing pattern observed. Thus, we sequenced genomic DNA from each of the 5-FU-sensitive/ resistant cell line pairs as well as a commercially available genomic DNA sample (Figure 4a and Supplementary Tables  8 and 9 ).
In all cell lines, a total of 33 single-nucleotide variations relative to the human reference genome (hg18) were identified in the genomic DNA amplicons covering all four splice sites involved in the splicing of exon 2 ( Figure 4a , Supplementary Tables 9 and 10). Of these, 28 were known polymorphisms in dbSNP. 22 Two variants were novel relative to dbSNP, but found in both sensitive cells (RKO) and the resistant derivative (RKO/5FU) ( Table 3) . Three variants appeared to be specific to a 5-FU-resistant cell line.
The first is a heterozygous splice site mutation at the acceptor splice site of exon 2 that is present in the MIP/5FU (resistant) cell line but not the MIP101 (sensitive) cell line (5727G4T in Figure 4 , Table 3 and Supplementary Table 9 ). For all pre-mRNAs generated from this mutated allele, the splicing machinery would not recognize the exon 2 acceptor site, resulting in aberrant splicing to yield isoform B transcripts that do not contain exon 2. A heterozygous mutation at the exon 2 acceptor site would create an approximately equal mixture of isoform A (wild type, full form) and isoform B (variant, short form); this is consistent with the observed data for MIP/5FU (Figure 1 ). It is possible that this mutation might act as a loss of function that confers resistance due to a gene dosage effect. The loss-offunction supposition is supported by the absence of isoform B protein (B33 kDa) in the immunoblots ( Supplementary  Figures 2-4) . A second heterozygous mutation is present in the resistant RKO/5FU cells. This mutation is predicted to result in an amino-acid substitution within the UMPS Uridine monophosphate synthetase and fluorouracil resistance
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OPRTase domain (5809C4T, P80S, Figure 4 and Table 3 ). A third heterozygous mutation present in the resistant MIP/ 5FU cells is predicted to result in an amino-acid substitution within UMPS exon 3 (8211C4T, R107C, Figure 4 and Table 3 ). It is predicted to be nonconservative by BLOSUM62 substitution matrix scores, SIFT and PolyPhen 23, 24 (Table 3 ). To further investigate the possible role of UMPS in 5-FU resistance, we compared 5-FU-exposed versus -naive tissue samples from patients.
Sequencing of UMPS in colorectal cancer samples
The 90 patient samples consisted of 24 primary colon tumors, 22 primary rectal tumors and 44 colorectal liver metastases. Of these, 55% were 5-FU exposed. We hypothesized that, like in the cell lines, exposure to 5-FU might select for cells bearing mutations in UMPS. To this end, we sequenced the exons of UMPS using genomic DNA from each sample (Figure 4a and Supplementary Tables 8 and 9 ).
A total of 40 single-nucleotide variants in UMPS relative to the human reference genome were identified. Of these, 27 were known polymorphisms in dbSNP. 22 Of the 13 putative novel mutations identified, 5 were within an intron (but not at a splice site), 1 was within exon 2b (Figure 4a ), 1 was at the À3 position of the acceptor splice site of exon 2 and the remaining 6 were coding mutations within exons 2, 3, 4 and 6. All but 2 of the 13 mutations were heterozygous.
Interestingly, the heterozygous splice site cancer-specific mutation (5725G4T in Figure 4 , Table 3 and Supplementary  Table 9 ) observed in patient 14 occurred only 2 bp from the splice site mutation observed in the MIP/5FU cell line. Aberrant splicing of exon 2 as observed in the cell line MIP/ 5FU was not apparent by RT-PCR (Supplementary Figure 6b) or the quantitative RT-PCR. Patient 14 also had a heterozygous missense mutation within exon 2 (5731G4A, A54T, Figure 4 , Table 3 and Supplementary Table 9 ). The patient's cancer that harbored these two mutations was aggressive. This patient presented with stage 4 disease with multiple local (13/16 lymph nodes) and distant metastases. Despite primary tumor resection and adjuvant chemotherapy with 5-FU, leucovorin and oxaliplatin, disease progression resulted in death within 3 months of the primary resection.
The remaining five putative coding mutations were identified in five separate cancers, and 4/5 were in 5-FUexposed cancers. The functional impact of all coding mutations was assessed by BLOSUM62, SIFT and PolyPhen-2 23, 24 (Table 3 and Supplementary Tables 10 and 11 ). The Q355E mutation is predicted as tolerated or benign but the remaining six coding mutations are considered damaging or probably damaging. Given the high degree of conservation at the UMPS locus, the predicted damaging effect of these mutations is not surprising. We further predict that each of the six damaging mutations would result in reduced UMPS activity, reduced activation of 5-FU and thus increased resistance to 5-FU. The number of mutations in posttreatment samples versus pre-treatment samples was not significantly more than expected by chance for either the entire set of 13 mutations (P ¼ 0.06; Fisher's exact test) or for the 6 mutations predicted to affect amino-acid sequence (P ¼ 1).
Discussion
Using a combination of novel and conventional approaches, we observed in cell lines: (1) increased abundance of UMPS isoform B (lacking exon 2) in MIP/5FU, presumably caused by a heterozygous splice site mutation, (2) increased abundance of isoform B in HCT/5FU (via an unknown molecular mechanism) and (3) expression of a mutant isoform A containing a protein coding change in RKO/5FU (also involving exon 2). In pretreatment colorectal tumors that we observed, UMPS isoform B mRNA was generally present but represented a minor form relative to isoform A. We also detected the presence of exon 2 skipping (the distinctive feature of isoform 2) in 46 of 57 tissues, tumors and cell lines by ALEXA-seq analysis of RNA-seq data sets.
15 Figure 4 Overview of single-nucleotide polymorphisms (SNPs) and mutations found by genomic sequencing. The position of amplicons used for sequencing reactions as well as putative novel mutations are depicted in relation to the coordinates of uridine monophosphate synthetase (UMPS) exons (black boxes) and introns (connecting lines). The position of each amplicon is depicted as a gray rectangle (see Supplementary Materials for primer sequences). Note that the coordinates displayed are relative to a fragment of UMPS genomic DNA with 1 kb of flank added (see Table 3 for corresponding chromosome coordinates). Intronic mutations are indicated in magenta, splice site mutations in red and protein coding mutations in blue. Additional details on each putative mutation are provided in Table 3 . (a) A total of 22 PCR amplicons (labeled A1 to A22) were generated from genomic DNA isolated from 6 cell lines (MIP101, MIP/5FU, RKO, RKO/5FU, HCT116 and HCT/5FU) and 1 reference sample (see Materials and methods). Sequencing of the genomic region of UMPS in these cell lines revealed a heterozygous splice site mutation (position 5727 G/G-G/T; indicated in red) at the splice acceptor site of exon 2 that was present in MIP/5FU (fluorouracil (5-FU) resistant) but not in MIP101 (sensitive) cells. This splice site mutation, acquired in the resistant cells, is predicted to prevent pre-mRNA splicing of exon 2 and favor production of isoform B from the mutated allele. Four additional mutations were observed (discussed in the text). (b) A total of 22 PCR amplicons (labeled A23 to A44) were generated from genomic DNA isolated from 188 colorectal cancer patient samples (see Materials and methods). In all, 12 putative mutations were identified, of which 5 were intronic, 1 was close to the same acceptor splice site mutation noted in panel a and 6 were mutations within the open reading frame (discussed in the text).
In addition to isoform B, we identified eight additional novel UMPS isoforms. The transcript structure and predicted protein content of these isoforms suggest that most are likely to be nonfunctional, either by nonsense mediated decay or disruption of the OPRTase domain of UMPS. The cell line with the lowest expression of isoform A (MIP/5FU) also had the highest resistance to 5-FU. The amount of isoform B and the ratio of isoform A/B varies considerably across the three pairs of drug-sensitive/resistant cell lines but the cell line with the highest level of isoform B also had the highest 5-FU half-maximal inhibitory concentration (IC 50 ). Our western analysis suggests that although UMPS isoform B and other isoforms are prevalent at the RNA level in resistant cells, at the protein level, they do not appear to be expressed at detectable levels. Thus, the functional consequence of alternative UMPS isoforms, of which isoform B was the most prevalent, is most likely a loss of function. It is possible however that a low isoform A/B ratio might in itself be predictive of 5-FU resistance. Larger numbers of 5-FUsensitive/resistant cell lines would be required to demonstrate this relationship. Gastric cancer cell lines that overexpress UMPS isoform A have increased sensitivity to 5-FU. 25 Our MIP101 UMPS knockdown experiment also suggests that UMPS may contribute, in part, to the difference in 5-FU sensitivity between the parent-sensitive MIP101 and the derivativeresistant MIP/5FU cell lines. The siRNA knockdown of UMPS isoform A resulted in less UMPS protein and ultimately a threefold increase in drug resistance. However, it remains to be determined whether the greater 5-FU resistance was due to impaired cellular growth (due to the loss of endogenous functions of UMPS) or whether a decrease in UMPS enzymatic activity impaired the ability of the cells to activate 5-FU to its cytotoxic metabolites.
Within colorectal cancer patient samples, four of the eight novel mutations discovered fell within the OPRTase domain, which is the catalytic domain responsible for 5-FU activation to fluorouridine monophosphate. 16 The other four fell within the ODCase domain, which is involved in normal pyrimidine biosynthesis but not for bioactivation of 5-FU. 16 Whereas these eight heterozygous mutations might confer selective advantage in the presence of 5-FU by reducing the activation of 5-FU or slowing cell growth, homozygous mutations are perhaps unlikely to occur because of the importance of UMPS in providing pyrimidines for the normal functioning of the cell. In support, homozygous mutations of UMPS have not, to our knowledge, been reported in humans, and UMPS enzymatic deficiency caused by a homozygous inherited nonsense point mutation causes early embryonic death in cattle. 26, 27 Moreover, inherited heterozygous UMPS loss-of-function point mutations are associated with 'Orotic Aciduria I' (Online Mendelian Inheritance in Man (OMIM): 258900), 28 a rare disease that is fatal unless treated with large doses of uridine.
Examination of public databases that catalog inherited variants in humans and/or acquired mutations in cancers, such as OMIM, COSMIC, HGMD and LOVD, suggest Coordinates relative to chromosome 3 (chr3) and the location with respect to UMPS exon and intron boundaries. that variants in UMPS and the OPRTase domain in particular are exceedingly rare. Specifically, database mining found no additional nonsynonymous mutations, and COSMIC reports only one heterozygous silent mutation in 1 of 101 renal carcinomas. 29 The absence of homozygous UMPS deficiency suggests that UMPS may be a dosage-sensitive locus. If so, loss of function of one copy of UMPS, such as by expression of a nonfunction isoform from one allele, as we observed in MIP/5FU cells, might be sufficient to contribute to a 5-FU-resistance phenotype. Based on the deleterious effect of UMPS deficiency, germline mutations that might cause intrinsic 5-FU resistance are expected to be rare. Somatic mutations, like those we report, that are acquired during tumorigenesis or chemotherapy treatment may contribute to acquired 5-FU resistance in colorectal cancer. Homozygous somatic mutation of UMPS is perhaps still unlikely.
Based on our observations, the inconsistent correlation between UMPS expression and 5-FU response or patient outcomes previously reported in the literature might be because of the failure to consider transcript structure and mutational status of UMPS. For example, a shift in the relative expression levels of UMPS isoforms A and B might have an effect on overall UMPS activity but would be undetectable by previously reported assays that measured the 3 0 end of UMPS. 8, 30 Similarly, the expression level might remain unchanged but UMPS activity might be reduced by the presence of point mutations that affect the protein sequence. Future studies on the role played by UMPS in 5-FU resistance should consider not just the level of UMPS mRNA abundance but also the expression of alternative UMPS isoforms as well as the mutational status of the gene. Improved understanding of the mechanisms of 5-FU resistance will also drive the development of new treatments that avoid or overcome resistance.
